{"id":357,"date":"2022-02-01T08:52:00","date_gmt":"2022-02-01T08:52:00","guid":{"rendered":"https:\/\/www.snijderlab.org\/news\/?p=357"},"modified":"2022-08-06T11:08:29","modified_gmt":"2022-08-06T11:08:29","slug":"exalt-1-study-published-in-cancer-discovery","status":"publish","type":"post","link":"https:\/\/www.snijderlab.org\/news\/2022\/02\/01\/exalt-1-study-published-in-cancer-discovery\/","title":{"rendered":"EXALT-1 study @ Cancer Discovery"},"content":{"rendered":"
\n
\"\"<\/a>
Pharmacoscopy-based Functional Precision Medicine<\/figcaption><\/figure>\n<\/div>\n\n\n

Our landmark EXALT-1 clinical study<\/a> (clinical trial NCT03096821<\/a>) was just published in Cancer Discovery. Here, we could demonstrate for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial. For 56 patients suffering aggressive blood cancers, their next treatment was adapted to their personal drug screening (pharmacoscopy) results, and we followed them on average for another 2 years. The results: <\/p>\n\n\n\n

“30 Patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease.”<\/p>Kornauth et al., Cancer Discovery, 2022<\/cite><\/blockquote>\n\n\n\n

Prof. Dr. Tony Letai, professor in Medicine at Harvard Medical School and Dana Farner Cancer Institute, has written a great accompanying commentary<\/a> as well as review<\/a> on the topic. <\/p>\n\n\n\n

Also check out the News article at the ETH Zurich<\/a>!<\/p>\n","protected":false},"excerpt":{"rendered":"

Our landmark EXALT-1 clinical study (clinical trial NCT03096821) was just published in Cancer Discovery. Here, we could demonstrate for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial. For 56 patients suffering aggressive blood cancers, their next treatment was adapted to their personal drug screening (pharmacoscopy) results, and we… Continue reading EXALT-1 study @ Cancer Discovery<\/span> →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,5],"tags":[],"class_list":["post-357","post","type-post","status-publish","format-standard","hentry","category-news","category-publications"],"_links":{"self":[{"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/posts\/357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/comments?post=357"}],"version-history":[{"count":4,"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/posts\/357\/revisions"}],"predecessor-version":[{"id":376,"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/posts\/357\/revisions\/376"}],"wp:attachment":[{"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/media?parent=357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/categories?post=357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.snijderlab.org\/news\/wp-json\/wp\/v2\/tags?post=357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}